Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249379 · ClinicalTrials.gov registry record · Phase 4
Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT00249379 is a Phase 4 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 26 participants.
The verdict
NCT00249379, a Phase 4 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to test how tolerable and effective acamprosate is when used to prevent alcohol relapse in criminal justice supervisees (those on probation, parole, or in drug court).
Interventions
- DRUG Acamprosate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249379
The ClinicalTrials.gov registry entry for NCT00249379 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acamprosate is the first listed.
NCT00249379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249379 about?
NCT00249379 is a clinical study titled "Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees". The purpose of this study is to test how tolerable and effective acamprosate is when used to prevent alcohol relapse in criminal justice supervisees (those on probation, parole, or in drug court).
What is the current status of trial NCT00249379?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2005-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00249379?
The interventions under investigation include: Acamprosate (DRUG).
Who is sponsoring clinical trial NCT00249379?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.